Wall Street brokerages expect Charles River Laboratories Intl. Inc (NYSE:CRL) to post earnings of $1.39 per share for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Charles River Laboratories Intl.’s earnings. The highest EPS estimate is $1.46 and the lowest is $1.36. Charles River Laboratories Intl. reported earnings per share of $1.30 during the same quarter last year, which would indicate a positive year over year growth rate of 6.9%. The firm is scheduled to report its next earnings report on Thursday, November 8th.

On average, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $5.91 per share for the current fiscal year, with EPS estimates ranging from $5.88 to $5.97. For the next financial year, analysts forecast that the business will report earnings of $6.38 per share, with EPS estimates ranging from $6.22 to $6.50. Zacks’ EPS calculations are an average based on a survey of analysts that cover Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the Zacks’ consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company had revenue of $585.30 million for the quarter, compared to analyst estimates of $570.65 million. During the same quarter last year, the firm posted $1.29 earnings per share. The company’s quarterly revenue was up 24.8% compared to the same quarter last year.

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group boosted their target price on shares of Charles River Laboratories Intl. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Barclays boosted their target price on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 9th. Bank of America boosted their target price on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, July 16th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 target price on the stock in a research report on Friday, May 11th. Finally, ValuEngine raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 18th. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Charles River Laboratories Intl. has a consensus rating of “Buy” and an average target price of $122.00.

In other Charles River Laboratories Intl. news, CEO James C. Foster sold 5,005 shares of Charles River Laboratories Intl. stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $110.80, for a total transaction of $554,554.00. Following the sale, the chief executive officer now owns 296,676 shares in the company, valued at $32,871,700.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Birgit Girshick sold 3,978 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, July 17th. The stock was sold at an average price of $119.90, for a total transaction of $476,962.20. Following the sale, the insider now owns 18,999 shares in the company, valued at approximately $2,277,980.10. The disclosure for this sale can be found here. Insiders have sold 33,258 shares of company stock worth $4,001,244 in the last quarter. Corporate insiders own 2.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Signaturefd LLC acquired a new stake in Charles River Laboratories Intl. during the first quarter worth $105,000. NumerixS Investment Technologies Inc acquired a new stake in Charles River Laboratories Intl. during the second quarter worth $122,000. Adviser Investments LLC acquired a new stake in shares of Charles River Laboratories Intl. in the 1st quarter valued at $152,000. Wsfs Capital Management LLC acquired a new stake in shares of Charles River Laboratories Intl. in the 2nd quarter valued at $203,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Charles River Laboratories Intl. in the 2nd quarter valued at $212,000. Hedge funds and other institutional investors own 98.02% of the company’s stock.

CRL stock traded up $0.54 on Tuesday, reaching $121.13. 316,702 shares of the company were exchanged, compared to its average volume of 371,076. Charles River Laboratories Intl. has a 12 month low of $96.70 and a 12 month high of $130.66. The firm has a market capitalization of $5.79 billion, a P/E ratio of 22.98, a price-to-earnings-growth ratio of 1.51 and a beta of 0.66. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.